Lung cancer trials in Portugal

In Portugal 43 Also abroad 2733

43 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Braga, Porto
Age
18 years and over
People
854 worldwide
Run by
AbbVie
See details and how to joinNCT07005102
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Braga, Guimaraes, Loures, Porto, Senhora Da Hora
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
Phase 1Taking people
A Study of ZW251 in Participants With Advanced Solid Tumors
Where
Lisbon, Vila Nova de Gaia
Age
18 years and over
People
140 worldwide
Run by
Zymeworks BC Inc.
See details and how to joinNCT07164313
Phase 3Taking people
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Where
Coimbra, Lisbon, Porto, Vila Nova de Gaia
Age
18 years and over
People
363 worldwide
Run by
OSE Immunotherapeutics
See details and how to joinNCT06472245
Phase 3Taking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
Cascais, Lisbon, Porto
Age
18 years and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
Braga, Cascais, Coimbra, Lisbon, Loures, Porto, Senhora Da Hora
Age
18 years and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
Phase 3Taking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
Braga, Coimbra, Faro, Lisbon, Porto
Age
18 years and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00
Phase 1Taking people
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Where
Porto
Age
18 years and over
People
62 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521702-18-00 · EU 2025-521702-18-00
Phase 3Taking people
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
Where
Braga, Lisbon, Porto, Senhora Da Hora
Age
18 years and over
People
168 worldwide
Run by
Amgen Inc.
See details and how to join2026-525489-23-00 · EU 2026-525489-23-00
No phaseNot yet taking people in Portugal
Family-centred Pulmonary Rehabilitation to Empower Carers
Where
Aveiro, Figueira da Foz Municipality, Lisbon, Matosinhos Municipality, Santa Maria da Feira, Vila Nova de Gaia
Age
18 years and over
People
120
Run by
Aveiro University
See details and how to joinNCT07791147
Phase 3Taking people
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Lisbon, Senhora Da Hora
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00 · EU 2024-520050-38-00
Phase 3Taking people
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Where
Coimbra, Guimaraes, Lisbon, Porto
Age
18 years and over
People
540 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00
Phase 2Taking people
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Lisbon, Matosinhos, Porto
Age
18 years and over
People
204 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00
No phaseNot yet taking people in Portugal
CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS
Where
Lisbon
Age
18 years and over
People
140
Run by
Universidade Nova de Lisboa
See details and how to joinNCT07630246
Phase 2/3Taking people
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Adult Participants with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Braga, Porto
Age
18 years and over
People
50 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2024-518586-10-00 · EU 2024-518586-10-00
Phase 3Taking people
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Where
Braga, Faro, Lisbon, Porto
Age
18 years and over
People
300 worldwide
Run by
Maia Biotechnology
See details and how to joinNCT06908304 · EU 2024-520164-33-00
No phaseNot yet taking people in Portugal
Prehabilitation for Lung Cancer Patients Undergoing Lung Resection
Where
Porto
Age
18 years and over
People
200
Run by
Universidade do Porto
See details and how to joinNCT06802627
Phase 1/2Taking people
Neoadjuvant Immunotherapy with Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) followed by Radical Radiotherapy or Chemoradiotherapy – IDEAR
Where
Porto
Age
18 years and over
People
30
Run by
Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.
See details and how to join2024-518804-32-00 · EU 2024-518804-32-00